{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:57:15Z","timestamp":1740149835831,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12288-021-01490-1","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T18:06:29Z","timestamp":1632161189000},"page":"585-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Experience of Nivolumab Prior to Autologous Stem Cell Transplant for Relapsed Refractory Hodgkin Lymphoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Jaikumar","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-7928","authenticated-orcid":false,"given":"Akanksha","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinnari","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamlesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanket","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsha","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurva","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"1490_CR1","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1200\/JCO.2005.05.016","volume":"23","author":"JM Connors","year":"2005","unstructured":"Connors JM (2005) State-of-the-art therapeutics: Hodgkin\u2019s lymphoma. J Clin Oncol 23:6400\u20136408","journal-title":"J Clin Oncol"},{"key":"1490_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/725219","volume":"2011","author":"P Shenoy","year":"2011","unstructured":"Shenoy P, Maggioncalda A, Malik N, Flowers CR (2011) Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv Hematol 2011:1\u201311","journal-title":"Adv Hematol"},{"issue":"2","key":"1490_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/PPO.0b013e3181a1438a","volume":"15","author":"F Quddus","year":"2009","unstructured":"Quddus F, Armitage JO (2009) Salvage therapy for Hodgkin\u2019s lymphoma. Cancer J 15(2):161\u2013163","journal-title":"Cancer J"},{"key":"1490_CR4","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","volume":"93","author":"SM Ansell","year":"2018","unstructured":"Ansell SM (2018) Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 93:704\u2013715","journal-title":"Am J Hematol"},{"issue":"3","key":"1490_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1634\/theoncologist.2011-0258","volume":"17","author":"R Ramchandren","year":"2012","unstructured":"Ramchandren R (2012) Advances in the treatment of relapsed or refractory Hodgkin\u2019s lymphoma. Oncologist 17(3):367\u2013376. https:\/\/doi.org\/10.1634\/theoncologist.2011-0258","journal-title":"Oncologist"},{"issue":"10","key":"1490_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/2040620717728000","volume":"8","author":"L Nikolaenko","year":"2017","unstructured":"Nikolaenko L, Chen R, Herrera AF (2017) Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Ther Adv Hematol 8(10):293\u2013302. https:\/\/doi.org\/10.1177\/2040620717728000","journal-title":"Ther Adv Hematol"},{"key":"1490_CR7","first-page":"2277","volume":"9","author":"R Chen","year":"2015","unstructured":"Chen R, Wang F, Zhang H, Chen B (2015) Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies. Drug Des Dev Ther 9:2277","journal-title":"Drug Des Dev Ther"},{"key":"1490_CR8","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36:1428","journal-title":"J Clin Oncol"},{"key":"1490_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319","journal-title":"N Engl J Med"},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"21","key":"1490_CR11","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA et al (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496","journal-title":"Blood"},{"key":"1490_CR12","unstructured":"CommonTerminologyCriteriaforAdverseEvents (CTCAE) version 4.03. In Edition U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute June 14, 2010"},{"key":"1490_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"issue":"14","key":"1490_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ et al (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134(14):1144\u20131153","journal-title":"Blood"},{"issue":"7","key":"1490_CR15","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-16-1387","volume":"23","author":"SM Ansell","year":"2017","unstructured":"Ansell SM (2017) Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res 23(7):1623\u20131626. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1387","journal-title":"Clin Cancer Res"},{"key":"1490_CR16","doi-asserted-by":"crossref","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL et al (2018) Phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory classic Hodgkin lymphoma: part 3 (concurrent dosing) results and updated progression\u2010free survival results from parts 1 and 2 (staggered dosing). ASH 1635","DOI":"10.1182\/blood-2018-99-110002"},{"issue":"S1","key":"1490_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hon.2589","volume":"37","author":"AS LaCasce","year":"2019","unstructured":"LaCasce AS (2019) Treating Hodgkin lymphoma in the new millennium: relapsed and refractory disease. Hematol Oncol 37(S1):87\u201391","journal-title":"Hematol Oncol"},{"key":"1490_CR18","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S et al (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283\u20131294","journal-title":"Lancet Oncol"},{"key":"1490_CR19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1182\/blood.V128.22.1106.1106","volume":"128","author":"CS Diefenbach","year":"2016","unstructured":"Diefenbach CS, Hong F, David KA et al (2016) A phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). Blood 128:1106","journal-title":"Blood"},{"issue":"10","key":"1490_CR20","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","volume":"28","author":"H Bek\u00f6z","year":"2017","unstructured":"Bek\u00f6z H, Karadurmu\u015f N, Payda\u015f S et al (2017) Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Oncol 28(10):2496\u20132502","journal-title":"Ann Oncol"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-021-01490-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T03:44:01Z","timestamp":1655783041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-021-01490-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s12288-021-01490-1","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"type":"print","value":"0971-4502"},{"type":"electronic","value":"0974-0449"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"assertion":[{"value":"12 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approved by the Institutional Review Board of the GCRI (IRC\/2021\/P-51).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}